Jeff Yass’s UroGen Pharma URGN Stock Holding History

Jeff Yass’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.08M	Sell	111,000 -4,800	-4%	-$130K	﹤0.01%	5004
2026 Q1	$2.08M	Sell	115,800 -5,200	-4%	-$104K	﹤0.01%	6098
2025 Q4	$2.83M	Sell	121,000 -50,200	-29%	-$1.09M	﹤0.01%	4973
2025 Q3	$3.42M	Sell	171,200 -145,900	-46%	-$2.62M	﹤0.01%	4732
2025 Q2	$4.34M	Buy	317,100 +284,300	+867%	+$2.73M	﹤0.01%	4243
2025 Q1	$363K	Buy	+32,800	New	+$350K	﹤0.01%	9642
2024 Q4	–	Sell	-44,600	Closed	-$566K	–	13288
2024 Q3	$566K	Sell	44,600 -12,900	-22%	-$191K	﹤0.01%	8164
2024 Q2	$965K	Buy	57,500 +30,600	+114%	+$435K	﹤0.01%	6687
2024 Q1	$404K	Buy	+26,900	New	+$440K	﹤0.01%	9015
2023 Q4	–	Sell	-18,500	Closed	-$259K	–	13347
2023 Q3	$259K	Buy	18,500 +5,200	+39%	+$83.5K	﹤0.01%	9671
2023 Q2	$138K	Buy	+13,300	New	+$147K	﹤0.01%	10663
2021 Q1	–	Sell	-13,400	Closed	-$241K	–	12887
2020 Q4	$241K	Sell	13,400 -18,600	-58%	-$390K	﹤0.01%	9728
2020 Q3	$617K	Sell	32,000 -77,900	-71%	-$1.76M	﹤0.01%	7234
2020 Q2	$2.87M	Buy	109,900 +11,300	+11%	+$276K	﹤0.01%	3871
2020 Q1	$1.76M	Sell	98,600 -21,400	-18%	-$578K	﹤0.01%	4198
2019 Q4	$4M	Buy	120,000 +45,700	+62%	+$1.25M	﹤0.01%	3288
2019 Q3	$1.77M	Buy	74,300 +58,900	+382%	+$1.93M	﹤0.01%	4459
2019 Q2	$553K	Buy	15,400 +3,300	+27%	+$122K	﹤0.01%	7074
2019 Q1	$447K	Buy	+12,100	New	+$507K	﹤0.01%	6492
2018 Q4	–	Sell	-7,500	Closed	-$354K	–	10015
2018 Q3	$354K	Buy	+7,500	New	+$348K	﹤0.01%	7148

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Jeff Yass's URGN Position: Q2 2026 in Review

Jeff Yass reduced its UroGen Pharma (URGN) stake by 92% in Q2 2026, selling an estimated $2.08M and leaving 6,782 shares worth $250K. The position accounts for ﹤0.01% of the portfolio, ranked #11467.

Jeff Yass first reported a position in URGN in Q3 2018 and has held it in 24 quarters since. The position peaked at $6.64M in Q2 2025. 188 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Jeff Yass held 6,782 shares of UroGen Pharma worth $250K as of Q2 2026.
Jeff Yass sold 76,841 UroGen Pharma shares in Q2 2026, an estimated $2.08M.
UroGen Pharma made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11467 holding.
Jeff Yass first reported a position in UroGen Pharma in Q3 2018 and has held it in 24 quarters since.
Jeff Yass's UroGen Pharma position peaked at $6.64M in Q2 2025.
188 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.